S&P 500

5.346,99

-0,11%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Lipella Pharmaceuticals Inc (LIPO)
Lipella Pharmaceuticals Inc (LIPO) Notícias

LIPO

Lipella Pharmaceuticals (LIPO)

Lipella Pharmaceuticals Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:LIPO

1 2 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
31/05/2024	09:00	GlobeNewswire Inc.	Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
29/05/2024	09:00	GlobeNewswire Inc.	Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
21/05/2024	09:00	GlobeNewswire Inc.	Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
15/05/2024	17:39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
09/05/2024	17:06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
06/05/2024	17:05	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
17/04/2024	09:00	GlobeNewswire Inc.	Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
05/04/2024	09:00	GlobeNewswire Inc.	Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
03/04/2024	09:00	GlobeNewswire Inc.	Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
07/03/2024	17:23	GlobeNewswire Inc.	PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
05/03/2024	10:00	GlobeNewswire Inc.	Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
27/02/2024	19:04	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
27/02/2024	18:51	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
20/02/2024	10:00	GlobeNewswire Inc.	Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
09/02/2024	02:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
07/02/2024	19:29	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
01/02/2024	18:09	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
03/01/2024	18:59	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
20/12/2023	10:00	GlobeNewswire Inc.	Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
28/11/2023	19:28	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
10/11/2023	10:00	PR Newswire (US)	FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
07/11/2023	19:22	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
01/11/2023	17:06	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
25/10/2023	17:05	PR Newswire (US)	Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
24/10/2023	09:00	PR Newswire (US)	Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
20/10/2023	09:00	PR Newswire (US)	Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
10/10/2023	17:05	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
21/09/2023	09:30	PR Newswire (US)	Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
23/06/2023	17:02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:LIPO	Lipella Pharmaceuticals Inc
21/06/2023	18:08	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:LIPO	Lipella Pharmaceuticals Inc